This immunotherapy drug helped me beat cancer - instead of $229k it now costs $31
A life-changing medication that gave a young Sydney woman with rare blood cancer a second chance has been approved for PBS ...
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' rating.
Pharmaceutical Technology on MSN20d
NICE green lights two blood cancer therapies for NHS use
BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
National Institute for Health and Care Excellence21d
New option for adult leukaemia patients as we recommend treatment
will be available immediately on the NHS. The treatment, called blinatumomab (also known as Blincyto), works in a completely new way. It helps the body's own immune system recognise and destroy cancer ...
precisionmedicineonline21d
UK's NICE Approves Blincyto as Frontline Consolidation Treatment for Certain Leukemia Patients
NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday approved Amgen's Blincyto (blinatumomab) with chemotherapy as a consolidation treatment for adult patients with ...
Pacbiztimes.com28d
Amgen applies for FDA approval of Blincyto
Thousand Oaks-based Amgen submitted an application for Blincyto to the U.S. Food and Drug Administration, the company announced on Feb. 14. Amgen aims to gain approval for Blincyto to treat ...